Other current positions

  • CEO of Triton Therapeutics, since 2025
  • Member of the Board of Directors of Amylyx Pharmaceuticals Inc., USA; Apnimed Inc., USA; Apellis Pharmaceuticals Inc., USA; and DalCor Inc., London / UK–four biotechnology companies
  • Executive in Residence at Canaan Partners (Venture Capital)

Previous positions and professional experience

  • Chairman of the Board of Directors of Corium Therapeutics Inc., until 2025
  • Member of the Board of Directors of Gelesis Inc., until 2023
  • Member of the Board of Directors of Covetrus Inc., until 2022
  • Member of the Board of Directors of ResTORbio Inc., until 2020
  • Member of the Board of Directors of AMAG Pharmaceutical Inc., until 2020
  • Member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Chairman of the Board of Directors and CEO of Boehringer Ingelheim USA and Country Managing Director for the U.S., 2012–2018; prior to that, Head of Global Marketing for Human Pharmaceuticals, Germany, 2008–2011, and Head of Human Pharmaceuticals, U.S., 2003–2008
  • Various positions at Merck & Co., Inc., 1994–2003, and at Abbott Laboratories, Inc., 1987–1993
  • Chairman of the National Pharmaceutical Council (NPC)

Education

  • Carnegie Mellon University, Pittsburgh, MBA, 1985–1987
  • University of Brussels, Chemical Engineering
Back to Management